Authors : S. Kaviya; G. SivaKumar; P. Anandhasankar

Volume/Issue : Volume 11 - 2026, Issue 8 - August

Google Scholar : https://tinyurl.com/y9s226vm

Scribd : https://tinyurl.com/4tp6jerk

DOI : https://doi.org/10.38124/ijisrt/26aug368

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Pancreatic cancer is among the most aggressive neoplasms worldwide, with a significantly low five-year survival rate as reported in the literature. Pancreatic tumours are predominantly diagnosed as pancreatic ductal adenocarcinoma (PDAC), which is characterized by poor prognosis, late diagnosis, aggressive progression, and resistance to standard chemotherapy. Recent advances in the field of molecular and genomic biology have improved the understanding of the genetic underpinnings of this disease. The review discusses the key genetic drivers of pancreatic carcinogenesis, including KRAS, TP53, CDKN2A, SMAD4, and BRCA1/2. The mechanisms of action of these genes and their impact on the signaling pathways involved in the development and progression of PDAC are described. These genes encode proteins that participate in the regulation of the MAPK signaling pathway, cell cycle progression, TGF-β signaling pathway, and homologous recombination DNA repair mechanisms. The review emphasizes the role of these genes as therapeutic biomarkers for the development of targeted molecular therapy. The current management strategies targeting these mechanisms and the emerging therapeutic agents that may be considered in the future for the management of patients with pancreatic cancer are discussed.

Keywords : Pancreatic Cancer, PDAC, KRAS, TP53, CDKN2A, SMAD4, BRCA, Targeted Therapy, Molecular Pathway.

References :

1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
2. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039–1049.
3. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.
4. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501.
5. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399–405.
6. Collins MA, Pasca di Magliano M. Oncogenic KRAS in pancreatic cancer. Nat Rev Cancer. 2012;12(10):697–709.
7. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014;13(11):828–851.
8. Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor sotorasib drives anti-tumour immunity. Nature. 2019;575(7781):217–223.
9. Fakih M, O’Neil B, Price TJ, Falchook GS, Desai J, Kuo J, et al. Adagrasib in KRAS G12C–mutated solid tumors. N Engl J Med. 2022;387(2):120–131.
10. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol. 2007;25(15):1960–1966.
11. Muller PAJ, Vousden KH. Mutant p53 in cancer: New functions and therapeutic opportunities. Nat Rev Cancer. 2013;13(2):83–96.
12. Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18(2):89–102.
13. Lehmann BD, Pietenpol JA. Targeting mutant p53 in human tumors. Cancer Cell. 2012;21(3):319–320.
14. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844–848.
15. Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672–1677.
16. Knudsen ES, Witkiewicz AK. The strange case of CDK4/6 inhibitors: Mechanisms, resistance, and combination strategies. Nat Rev Clin Oncol. 2017;14(9):575–588.
17. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936.
18. Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res. 2016;22(10):2380–2385.
19. Massagué J. TGF-β in cancer. Cell. 2008;134(2):215–230.
20. Ikushima H, Miyazono K. TGF-β signalling: A complex web in cancer progression. Nat Rev Cancer. 2010;10(6):415–424.
21. Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, et al. Galunisertib plus gemcitabine vs gemcitabine for untreated pancreatic cancer. Clin Cancer Res. 2018;24(21):5506–5515.
22. Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, et al. Clinical development of galunisertib (LY2157299), a small molecule inhibitor of TGF-β signaling pathway. Clin Cancer Res. 2015;21(7):1505–1512.
23. Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158.
24. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921.
25. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–917.
26. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–327.
27. O’Reilly EM, Lee JW, Zalupski M, Capanu M, Park JO, Golan T, et al. Randomized phase II trial of gemcitabine and cisplatin with or without veliparib in pancreatic cancer. J Clin Oncol. 2018;36(15):1375–1382.
28. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.
29. Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, et al. Real-time genomic characterization of advanced pancreatic cancer. Nat Rev Cancer. 2018;18(8):505–518.
30. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846–4861.
31. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–1617.
32. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–620.
33. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73–85.
34. Jones S, Zhang X, Parsons DW, Lin JCH, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–1806.
35. Iacobuzio-Donahue CA. Genetic evolution of pancreatic cancer: Lessons learnt from the pancreatic cancer genome sequencing project. Nat Rev Cancer. 2012;12(10):705–713.
36. Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: Current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333–348.
37. Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma. Clin Cancer Res. 2021;27(5):1327–1334.
38. Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: Is the undruggable drugged? Nat Rev Cancer. 2020;20(9):533–552.
39. Perkhofer L, Gout J, Roger E, Jäger C, Klöppel G, Kleger A. Molecular targeted therapy in pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(11):787–803.
40. Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: An update on therapeutic targeting strategies. Nat Rev Cancer. 2020;20(8):457–471.
41. Bear AS, Vonderheide RH, O’Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. J Clin Oncol. 2020;38(16):1825–1835.
42. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20(10):1218–1249.
43. Collins MA, Bednar F, Zhang Y, Brisset JC, Galbán S, Galbán CJ, et al. Oncogenic KRAS is required for pancreatic tumor maintenance. Oncogene. 2014;33(38):4495–4505.
44. Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics. Nature. 2017;546(7657):71–78.
45. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6):437–450.